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CASE REPORT
RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL 
MEGLUMINE ANTIMONIATE
Erica de Camargo Ferreira e VASCONCELLOS(1), Maria Inês Fernandes PIMENTEL(1), Cláudia Maria VALETE-ROSALINO(1,2),  
Maria de Fátima MADEIRA(1) & Armando de Oliveira SCHUBACH(1,3)
SUMMARY
We report a case of a 42 year-old female, who came to a leishmaniasis reference center in Rio de Janeiro, Brazil, presenting a 
cutaneous leishmaniasis lesion in the right forearm. Treatment with low-dose intramuscular meglumine antimoniate (MA) (5 mg 
Sb5+/kg/day) was initiated, with improvement after 28 days, although with the development of generalized eczema. After 87 days, the 
lesion worsened. Patient refused treatment with amphotericin B. MA was then infiltrated in the lesion, in two sessions, resulting in 
local eczema, with bullae formation; however, twenty days after, both the ulcer and eczema receded. Intralesional administration of 
MA should be used carefully when previous cutaneous hypersensitivity is detected.
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CASE REPORT
American tegumentary leishmaniasis (ATL) is an infectious disease 
caused by protozoa of Leishmania genus, transmitted by female sandflies 
(Phlebotominae). Few medications are efficient in its treatment, among 
them meglumine antimoniate (MA). Due to the difficulties linked to the 
administration of MA, less toxic alternative therapies with low doses or 
intralesional injections (IL) of MA have been studied5,6. We report a case 
of a patient who presented resolution of cutaneous leishmaniasis (CL) 
after development of acute eczema in the site of the injection of MA.
A 42 year-old white female, who signed a free informed consent form, 
came to the Leishmaniasis Surveillance Laboratory, Evandro Chagas 
Clinical Research Institute, Oswaldo Cruz Foundation, Rio de Janeiro, 
Brazil, presenting a CL lesion in the right forearm for 45 days. Imprint 
of the lesion showed amastigotes parasites, and Leishmania (Viannia) 
braziliensis was identified from the culture of a fragment of the lesion 
obtained through biopsy. Mucosal lesions were not seen in fiber optic 
otorhinolaryngological examination of the upper airways and digestive 
tract. Treatment with low-dose intramuscular (IM) MA - 5 mg Sb5+ per 
kilogram per day - was initiated (Aventis, São Paulo, Brazil). After a 
28-day treatment, she improved. However, she presented generalized 
eczema, treated with oral dexclorpheniramine and dexametasone 
ointment. After 87 days, the ulcer worsened (Fig. 1A). The second choice 
drug, amphotericin B desoxycolate, was offered to the patient, but she 
refused to be hospitalized and reported difficulties in going to the hospital 
three times a week to receive the medication in a day-hospital regimen. 
Alternative drugs such as pentamidine and liposomal amphotericin B 
were not available. Treatment was started with 7 mL of MA, without any 
diluents, injected into the lesion edge until its whole base got infiltrated. 
She developed moderate local eczema. Oral dexchlorpheniramine was 
prescribed and the ulcer improved. After 13 days, a second IL MA 
injection was made, with 5 mL of this drug, and the eczema worsened, 
with bullae formation (Fig. 1B); however, twenty days after, both ulcer 
and eczema receded (Fig. 1C).
IL way of administration is a viable alternative to systemic MA 
in older people or in conditions in which systemic treatment is not 
tolerated, due to its efficacy and infrequent, slight to moderate adverse 
events5,6. Local therapy was considered unsuitable for the treatment of 
New World cutaneous leishmaniasis caused by L. (V.) braziliensis or 
L. (V.) panamensis because of the potential risk of mucosal metastasis; 
however, as systemic treatment does not guarantee prevention of later 
mucocutaneous leishmaniasis, which is found in less than 5% of 
the cases, local treatments should be explored. It is now considered 
acceptable to use local therapy in selected cases of New World 
cutaneous leishmaniasis. The World Health Organization states that 
in patients with mild disease or with comorbid conditions, treatments 
safer than systemic therapy should be preferred, even if the level of 
evidence for efficacy is weak7.
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ASTE et al. (1998) had a successful experience with this local therapy, 
with 11% of the patients presenting mild reactions, such as erythema 
or pruritus, without systemic adverse effects. Patients didn’t need to 
interrupt the treatment1.
CORDOBA et al. (2012) described a series of 70 patients with 
cutaneous leishmaniasis, treated with weekly intralesional infiltrations 
of MA (Glucantime®). Nine of them developed infiltrated itchy 
erythematous and vesiculous plaques at the injection sites. After 
cutaneous tests, they concluded that type IV hypersensitivity could be 
involved in the mechanism of the cutaneous reaction3.
Some other diseases have been occasionally treated with local 
drugs that induce hypersensitivity reactions; resolution of warts with 
dinitrochlorobenzene (DNCB) is well documented4. In an animal model 
with guinea pigs, DNCB inhibited the development of leishmaniasis 
cutaneous lesions, but only when applied in the infection sites2.
Probably, hypersensitivity to MA was involved in the resolution 
of the lesion in our patient. Although the response to treatment in the 
present case was excellent, the great intensity of the eczematous local 
cutaneous reaction is indicative that this way of administration should be 
used carefully as an alternative to systemic MA treatment, when previous 
cutaneous hypersensitivity is detected.
RESUMO
Resolução de leishmaniose cutânea após eczema agudo devido a 
antimoniato de meglumina intralesional
Relatamos caso de paciente de 42 anos atendida em centro de 
referência em leishmanioses no Rio de Janeiro, Brasil, apresentando 
lesão de leishmaniose cutânea no antebraço direito. Iniciado tratamento 
com baixa dose de antimoniato de meglumina (AM) intramuscular (5 mg 
Sb5+/kg/dia), houve melhora após 28 dias, porém com desenvolvimento de 
eczema generalizado. Após 87 dias, notou-se piora da lesão. A paciente 
recusou o tratamento com anfotericina B. Infiltrou-se AM na lesão em 
duas sessões, resultando em eczema local com bolhas. Entretanto, 20 
dias depois, tanto a úlcera quanto o eczema regrediram. A administração 
intralesional do AM deve ser utilizada com cautela em pacientes com 
hipersensibilidade cutânea a este fármaco.
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Fig. 1 - Lesion’s follow up: A - Ulcerated lesion, before the first intralesional infiltration, 
measuring 20 x 10 mm, with infiltrated erythematous borders, partially covered by crusts 
and with an epithelialized center of about 5 mm. B - Edema of the forearm and hand, after 
the second intralesional infiltration of the lesion with meglumine antimoniate. Infiltration, 
erythema and coalescing vesicles, turning into larger bubbles of up to 35 mm. C - Atrophic 
scar, with erythema, residual hyperpigmentation on the spot where the biggest bubble was 
located (49 days after the second intralesional meglumine antimoniate).
